Psilocybin and chemotherapy nerve damage is an unlikely pairing, but a study published in Science this month reports that two doses of the psychedelic, given before chemotherapy, prevented peripheral neuropathy in mice. The work comes from Moran Amit, Patrick Dougherty and colleagues at the University of Texas MD Anderson Cancer Center, and it is preclinical: no human has been treated yet.
What the mice showed
Chemotherapy-induced peripheral neuropathy is the numbness, tingling and cold sensitivity that drugs like cisplatin and paclitaxel leave in the hands and feet. It is one of the most common reasons patients cut their dose short, and there is no approved way to prevent it.
The MD Anderson team gave mice psilocybin ahead of cisplatin, paclitaxel or docetaxel, then tracked them through repeated treatment cycles. Pretreated animals kept their sensitivity to touch, kept the nerve endings in their skin, and did not develop the cold hypersensitivity that untreated animals did. The protection held across as many as six chemotherapy rounds after just two psilocybin doses. Crucially, the chemotherapy still shrank tumours as well as it did without psilocybin.
How it seems to work
The effect ran through the serotonin 5-HT2A receptor, the same receptor behind psilocybin’s psychedelic effects. Blocking it removed the protection. Downstream, psilocybin kept mitochondria moving along nerve fibres, so the nerve endings stayed supplied with energy while the chemotherapy did its damage elsewhere. Dougherty called it the first use of psilocybin as a neuroprotective agent rather than a psychiatric drug.
What it doesn’t show
Everything here is mouse and cell work. Mouse neuropathy models are imperfect, and a compound that protects rodent nerves does not always protect human ones. The paper also does not settle whether the protection needs a full psychedelic dose or whether a sub-hallucinogenic dose would do, which matters a great deal for patients already coping with cancer treatment.
That question goes to a Phase 2 trial, NeuroGuard (NCT07227909), which MD Anderson says is about to open for patients with several cancer types receiving neurotoxic chemotherapy. Until it reports, this is a promising mechanism with a clinical trial attached, not a treatment. For where the human evidence on psilocybin actually stands, see our review of psilocybin research for depression.
Source: MD Anderson research release, 3 Sept 2026; paper DOI 10.1126/science.aec6116.
